BMRN
NEUTRAL
$56.49
Live
BioMarin Pharmaceutical Inc. · NASDAQ
Target $88.87
(+57.3%)
$50.76
52W Range
$69.87
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 01, 2026
Market cap
$10.86B
P/E
32.28
ROE
5.9%
Profit margin
10.8%
Debt/Equity
0.11
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
60%
BMRN shows bullish fundamentals based on deterministic rules. Financial strength is strong (F-Score 8/9). Key strengths include strong valuation and growth metrics. Price trades at a 361.1% premium to fair value estimate ($12.25), limiting near-term upside from a valuation perspective.
Key Strengths
Strong financial trend (Piotroski F-Score: 8/9)
Strong revenue growth of 17.0%
Low debt with D/E ratio of 0.11
Key Risks
High valuation with P/E of 32.3
Premium vs Graham Number ($35.3)
Price trades at a 361.1% premium to fair value estimate ($12.25), limiting near-term upside from a valuation perspective.
AI Fair Value Estimate
Based on comprehensive analysis
$12.25
-78.3% below current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
43
Moderate
25
65
50
75
0
AI Verdict
BMRN shows bullish fundamentals based on deterministic rules. Financial strength is strong (F-Score 8/9). Key strengths include strong valuation and growth metrics.
Key drivers: Strong financial trend (Piotroski F-Score: 8/9), Strong revenue growth of 17.0%, High valuation with P/E of 32.3
Confidence
60%
Value
25/100
Rule-based valuation (P/E + Graham).
Positives
- Insufficient data for clear positives.
Watchpoints
- Premium 32.3x trailing earnings multiple.
- Trades above Graham Number.
- Price trades at a 361.1% premium to fair value estimate ($12.25), limiting near-term upside from a valuation perspective.
Future
65/100
Rule-based growth outlook.
Positives
- Revenue growth running at 17.0%.
Watchpoints
No urgent risks highlighted.
Past
50/100
Historical performance + price trend: Shares moved -27.4% over 5Y and -20.1% over 1Y.
Positives
- Insufficient data for clear positives.
Watchpoints
No urgent risks highlighted.
Health
75/100
Balance sheet & liquidity (Z-Score: N/A).
Positives
- Low D/E ratio (0.11).
Watchpoints
No urgent risks highlighted.
Dividend
0/100
Dividend policy fallback.
Positives
- Insufficient data for clear positives.
Watchpoints
- No regular dividend payments.
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$56.49
Analyst Target
$88.87
Upside/Downside
+57.3%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for BMRN and closest competitors.
Updated 2026-03-31
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
BMRN
BioMarin Pharmaceutical Inc.
Primary
|
-27.4% | -41.9% | -20.1% | +4.3% | -5.4% | +4.4% |
|
ENSG
The Ensign Group, Inc.
Peer
|
+116.3% | +96.7% | +49.7% | +1.9% | -5.3% | -3.9% |
|
ELAN
Elanco Animal Health Incorporated
Peer
|
-26.6% | +143.8% | +140.5% | +3.2% | -10.8% | -3.9% |
|
GH
Guardant Health, Inc.
Peer
|
-43.8% | +265.0% | +98.7% | +33.6% | -3.7% | -7.1% |
|
TEM
Tempus AI, Inc.
Peer
|
+41.1% | +41.1% | +38.6% | -38.6% | +20.9% | +23.5% |
BMR
BioMarin Pharmaceutical Inc.
Primary
5Y
-27.4%
3Y
-41.9%
1Y
-20.1%
6M
+4.3%
1M
-5.4%
1W
+4.4%
ENS
The Ensign Group, Inc.
Peer
5Y
+116.3%
3Y
+96.7%
1Y
+49.7%
6M
+1.9%
1M
-5.3%
1W
-3.9%
ELA
Elanco Animal Health Incorporated
Peer
5Y
-26.6%
3Y
+143.8%
1Y
+140.5%
6M
+3.2%
1M
-10.8%
1W
-3.9%
GH
Guardant Health, Inc.
Peer
5Y
-43.8%
3Y
+265.0%
1Y
+98.7%
6M
+33.6%
1M
-3.7%
1W
-7.1%
TEM
Tempus AI, Inc.
Peer
5Y
+41.1%
3Y
+41.1%
1Y
+38.6%
6M
-38.6%
1M
+20.9%
1W
+23.5%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
32.28
Forward P/E
8.39
PEG Ratio
N/A
P/B Ratio
1.78
P/S Ratio
3.37
EV/Revenue
3.09
EV/EBITDA
13.76
Market Cap
$10.86B
Profitability
Profit margins and return metrics
Profit Margin
10.83%
Operating Margin
22.48%
Gross Margin
52.81%
ROE
5.94%
ROA
5.58%
Growth
Revenue and earnings growth rates
Revenue Growth
+17.0%
Earnings Growth
N/A
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.11
Low debt
Current Ratio
5.21
Strong
Quick Ratio
3.25
Excellent
Cash/Share
$8.12
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.9B
Gross Margin
68.5%
Op. Margin
-5.1%
Net Margin
-5.3%
Total Assets
$7.6B
Liabilities
$1.5B
Equity
$6.1B
Debt/Equity
0.25x
Operating CF
$0.1B
CapEx
$-0.0B
Free Cash Flow
$0.1B
FCF Yield
57%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-04-30
$N/A
2026-02-23
$0.46
-17.9% surprise
2025-10-27
$0.12
-64.3% surprise
2025-08-04
$1.44
+39.4% surprise
Healthcare Sector Comparison
Comparing BMRN against 560 companies in the Healthcare sector
(34 bullish, 167 neutral, 359 bearish)
P/E Ratio
32.28
This Stock
vs
75.44
Sector Avg
-57.2%
(Discount)
Return on Equity (ROE)
5.94%
This Stock
vs
-88.14%
Sector Avg
-106.7%
(Below Avg)
Profit Margin
10.83%
This Stock
vs
-16.28%
Sector Avg
-166.5%
(Weaker)
Debt to Equity
0.11
This Stock
vs
2.66
Sector Avg
-96.0%
(Less Debt)
Revenue Growth
17.0%
This Stock
vs
124.04%
Sector Avg
-86.3%
(Slower)
Current Ratio
5.21
This Stock
vs
4.47
Sector Avg
+16.4%
(Stronger)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
BMRN
BioMarin Pharmaceutical Inc.
|
NEUTRAL | $10.86B | 32.28 | 5.9% | 10.8% | $56.49 | |
|
ENSG
The Ensign Group, Inc.
|
NEUTRAL | $11.1B | 32.47 | 16.9% | 6.8% | $189.94 | Compare |
|
ELAN
Elanco Animal Health Incorporated
|
NEUTRAL | $11.36B | - | -3.7% | -4.9% | $22.75 | Compare |
|
GH
Guardant Health, Inc.
|
NEUTRAL | $11.43B | - | -% | -42.4% | $87.17 | Compare |
|
TEM
Tempus AI, Inc.
|
BEARISH | $10.19B | - | -89.5% | -19.3% | $56.78 | Compare |
BMRN
BioMarin...
NEUTRAL
Mkt Cap
$10.9B
P/E
32.3
ROE
5.9%
Price
$56.49
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-16 | DAVIS GEORGE ERIC | Officer | Stock Award | 14,570 | - |
| 2026-03-16 | GUYER CHARLES GREG | Chief Technology Officer | Stock Award | 14,990 | - |
| 2026-03-16 | HARDY ALEXANDER | Chief Executive Officer | Stock Award | 62,440 | - |
| 2026-03-16 | HUBBARD CRISTIN | Officer | Stock Award | 15,410 | - |
| 2026-03-16 | FRIBERG GREGORY R | Officer | Stock Award | 19,150 | - |
| 2026-03-16 | MUELLER BRIAN R | Chief Financial Officer | Stock Award | 18,740 | - |
| 2026-03-11 | GUYER CHARLES GREG | Chief Technology Officer | Sale | 16,486 | $996,744 |
| 2026-02-26 | FRIBERG GREGORY R | Officer | Sale | 6,326 | $381,937 |
| 2026-02-26 | DAVIS GEORGE ERIC | Officer | Sale | 26,061 | $1,599,103 |
| 2026-02-25 | DAVIS GEORGE ERIC | Officer | Stock Award | 15,224 | - |
| 2026-02-25 | GUYER CHARLES GREG | Chief Technology Officer | Stock Award | 15,222 | - |
| 2026-02-25 | MUELLER BRIAN R | Chief Financial Officer | Stock Award | 16,482 | - |
| 2026-01-20 | RAMCHANDANI RASHMI VIRENDRA | Officer | Stock Award | 25,610 | - |
| 2025-12-30 | MEIER RICHARD A | Director | Gift | 500 | - |
| 2025-10-31 | GUYER CHARLES GREG | Chief Technology Officer | Stock Award | 379 | $19,985 |
DAVIS GEORGE ERIC
Officer
2026-03-16
14,570 shares
GUYER CHARLES GREG
Chief Technology Officer
2026-03-16
14,990 shares
HARDY ALEXANDER
Chief Executive Officer
2026-03-16
62,440 shares
HUBBARD CRISTIN
Officer
2026-03-16
15,410 shares
FRIBERG GREGORY R
Officer
2026-03-16
19,150 shares
MUELLER BRIAN R
Chief Financial Officer
2026-03-16
18,740 shares
GUYER CHARLES GREG
Chief Technology Officer
2026-03-11
16,486 shares
·
$996,744
FRIBERG GREGORY R
Officer
2026-02-26
6,326 shares
·
$381,937
DAVIS GEORGE ERIC
Officer
2026-02-26
26,061 shares
·
$1,599,103
DAVIS GEORGE ERIC
Officer
2026-02-25
15,224 shares
GUYER CHARLES GREG
Chief Technology Officer
2026-02-25
15,222 shares
MUELLER BRIAN R
Chief Financial Officer
2026-02-25
16,482 shares
RAMCHANDANI RASHMI VIRENDRA
Officer
2026-01-20
25,610 shares
MEIER RICHARD A
Director
2025-12-30
500 shares
GUYER CHARLES GREG
Chief Technology Officer
2025-10-31
379 shares
·
$19,985
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
BUY
23 analysts
B of A Securities
2026-03-11
Buy
Buy
Barclays
2026-03-04
Overweight
Overweight
HC Wainwright & Co.
2026-03-02
Neutral
Neutral
Freedom Broker
2026-03-02
Buy
Buy
Canaccord Genuity
2026-02-26
Buy
Buy
Bernstein
2026-02-25
Outperform
Outperform
Guggenheim
2026-02-25
Buy
Buy
HC Wainwright & Co.
2026-02-25
Neutral
Neutral
Oppenheimer
2026-02-24
Outperform
Outperform
Wells Fargo
2026-02-18
Overweight
Overweight
Past News Coverage
Recent headlines mentioning BMRN from our newsroom.
Newest → oldest
No matching news yet.